International Rx Shortages Summit Urges New Purchasing Models
This article was originally published in PharmAsia News
Value of continuous supply should be factor in reimbursement decisions, an International Pharmaceutical Federation report suggests.
You may also be interested in...
The heavily concentrated sterile injectable manufacturing industry is creating roadblocks to the success of the Accelerated Recovery Initiative; GPhA predicts crisis will linger for years to come.
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.